BM
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Fisher | Fisher Asset Management | $10M | 0.0% | 2026-06-30 |
| Dodge & Cox | Dodge & Cox | $2M | 0.0% | 2026-06-30 |
| Tweedy, Browne | Tweedy, Browne Company | $2M | 0.2% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Methodology breakdown computing — it will appear here on its own.
Bristol-Myers Squibb Co. (BMY) is currently considered not halal (non-compliant), per our secondary compliance provider (last assessed 2026-08-06). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computing the full ratio and business-activity breakdown for BMY — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 42.90 | NEUTRAL |
| Stochastic %K (14) | 0.44 | BUY |
| CCI (20) | -121.72 | BUY |
| Williams %R (14) | -99.56 | BUY |
| MACD (12,26,9) | -0.58 | SELL |
| ROC (10) | -5.65 | SELL |
| Momentum (10) | -3.82 | SELL |
| EMA (10) | 65.75 | SELL |
| SMA (10) | 66.27 | SELL |
| EMA (20) | 65.68 | SELL |
| SMA (20) | 66.24 | SELL |
| EMA (30) | 65.04 | SELL |
| SMA (30) | 65.70 | SELL |
| EMA (50) | 63.61 | BUY |
| SMA (50) | 63.27 | BUY |
| EMA (100) | 60.97 | BUY |
| SMA (100) | 59.83 | BUY |
| EMA (200) | 57.01 | BUY |
| SMA (200) | 57.60 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - General
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Background via Yahoo Finance — informational, not part of the verdict.
Average — needs more confirmation before sizing up
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 62 |
| ⏰ 4H | BEARISH | 44 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | RANGING | 234 |
Peer movement computing — it will appear here on its own.
BEARISH 0 buys · 1 sells
Recent: Holzer Phil M sold 16862 sh @ $67.50 (2026-08-25)
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
